Table 11.
Cost-effectiveness analysis (German model)
| Study | Costs, €mean (95% CI) | p Value | CUR, €/QALY (95% CI) | ICUR, €/QALY (95% CI) |
CURR, (95% CI) |
p Value | %CE25k | %CE30k | ICER €/QALYG (95% CI) |
∆C1000
€ |
∆E1000
QALYG |
| Brandes153 | 14 905 (14 586 to 15 225) | <0.001 | 24 292 (20 263 to 28 321) | 4421 (2090 to 6752) | 1.22 (1.10 to 1.35) | 0.061 | 53.57% | 76.5% | 28 706 (−5529 to 62 940) | 5 561 695 | 193.8 |
| Strik155 | 31 539 (30 863 to 32 215) | <0.001 | 61 250 (53 939 to 68 561) | 41 379 (37 491 to 45 267) | 3.08 (2.83 to 3.34) | <0.001 | 0.00% | 0.0% | 367 368 (−710 070 to 1 444 806) | 22 195 135 | 60.4 |
| Abacioglu156 | 14 379 (14 071 to 14 687) | <0.001 | 33 429 (30 717 to 36 141) | 13 558 (11 791 to 15 325) | 1.68 (1.57 to 1.80) | <0.001 | 0.12% | 1.8% | −92 957 (−352 869 to 166 956) | 5 035 150 | −54.2 |
| Berrocal157 | 16 721 (16 362 to 17 079) | <0.001 | 48 419 (39 174 to 57 665) | 28 548 (23 705 to 33 391) | 2.44 (2.16 to 2.71) | <0.001 | 0.31% | 0.7% | −43 717 (−91 130 to 3697) | 7 377 172 | −168.8 |
| WA (1–4) | 17 922 (17 538 to 18 306) | <0.001 | 39 967 (35 985 to 43 949) | 20 096 (17 787 to 22 405) | 2.01 (1.86 to 2.16) | <0.001 | 0.04% | 0.3% | −291 167 (−1 869 626 to 1 287 291) | 8 577 947 | −29.5 |
| WA (2–4) | 18 043 (17 657 to 18 430) | <0.001 | 40 845 (36 926 to 44 763) | 20 973 (18 692 to 23 255) | 2.06 (1.90 to 2.21) | <0.001 | 88.8% | 99.2% | −226 212 (−1 153 427 to 701 004) | 8 699 523 | −38.5 |
| WA (2–3)* | 18 138 (17 750 to 18 527) | <0.001 | 40 424 (36 758 to 44 091) | 20 553 (18 384 to 22 722) | 2.03 (1.89 to 2.18) | <0.001 | 0.02% | 0.2% | −302 629 (−1 934 133 to 1 328 875) | 8 794 882 | −29.1 |
| Sahinbas23 | 9344 (9199 to 9488) | 1.000 | 19 871 (17 719 to 22 024) | 0 | 1.00 | 1.000 | 88.8% | 99.2% | 0 | 0 | 0.0 |
*Main comparator.
∆C1000, costs difference per 1000 patients; %CE30k, %CE at CET €30 000; CUR, cost-utility ratio; ∆E1000, effect difference per 1000 patients (QALY gained); ICER, incremental cost-effectiveness ratio; mEHT, modulated electrohyperthermia; RCUR, relative CUR; TMZ, temozolomide; QALY, quality-adjusted life-year; QALYG, QALY gained.